Abstract: Objective To discuss the prognostic value of IGFBP-3 mRNA expression in glioblastoma （GBM）. Methods The genomic mRNA expression data and patients's clinical data from three different GBM datasets， TCGA， REMBARNDT and GSE16011 were obtained， and the prognostic value of IGFBP-3 mRNA expression in GBM patients were investigated using KaplanMeier method and multivariate Cox regression analysis. Results In the TCGA dataset， patients with higher IGFBP-3 mRNA expression were associated with shorter overall survival （OS） than patients with lower IGFBP-3 mRNA expression.the median OS was 14.3 months （95％ CI：12.5-16.1） vs. 15.9 months （95％ CI：13.7-18.1），with significant differences （P=0.002）； similarly， in another two validation datasets， patients in high expression groups had shorter OS than those in low expression groups： REMBRANDT dataset： 13.2 months （95％ CI：10.8-15.6） vs. 16.7 months （95％ CI:13.4-20.1）， with significant differences （P=0.036）； GSE16011 dataset： 7.4 months （95％ CI：6.6-8.3） vs. 13.1 months （95％ CI：9.2-17.0），with significant differences （P＜0.001）. Cox model indicated that the prognostic value of IGFBP-3 mRNA expression might be dependent on gene expression subtype of GBMs. Conclusion The present study revealed and validated the prognostic value of IGFBP-3 mRNA expression in GBM patients， and suggested its dependence on gene expression subtypes of GBMs.